Autoimmune hemolytic anemia in children

Area of Science:

• Pediatric Hematology
• Immunology
• Clinical Medicine

Background:

• This retrospective study analyzed the clinical and hematological profiles of 26 children diagnosed with warm autoimmune hemolytic anemia (AIHA).
• The study assessed treatment outcomes, focusing on the efficacy of oral prednisolone and identifying factors influencing response and relapse.
• Idiopathic AIHA was more prevalent than secondary AIHA, with pallor, fever, and jaundice as common presenting symptoms.

Discussion:

• Oral prednisolone demonstrated high remission rates (81%) in pediatric AIHA patients, highlighting its effectiveness as a first-line therapy.
• Relapse occurred in a subset of patients, but a second course of steroids was effective, with one case requiring cyclosporine A.
• No significant correlation was found between treatment response and demographic or hematological parameters, emphasizing AIHA's complex presentation.

Key Insights:

• Early intervention in pediatric autoimmune hemolytic anemia is crucial, as delayed treatment correlates with an increased risk of relapse.
• Oral prednisolone is a highly effective treatment for warm AIHA in children, offering a favorable prognosis for most patients.
• Cyclosporine A serves as a potential therapeutic option for refractory cases of pediatric AIHA.

Outlook:

• Further research could explore long-term outcomes and optimal management strategies for pediatric AIHA, including steroid-sparing agents.
• Investigating the immunopathogenesis of AIHA may reveal novel therapeutic targets for improving treatment efficacy and reducing relapse rates.
• Standardizing diagnostic and treatment protocols for pediatric AIHA can enhance clinical care and patient outcomes globally.